Imunon News

Imunon Inc. Files For Mixed Shelf Offering Up To $75M - SEC Filing

This registration statement contains: a base prospectus which covers the offering, issuance and sale by us of up to $75,000,000 in the aggregate of common stock, preferred stock, debt securities, warr

Benzinga04:27

Imunon Abstract On Phase 2 Study With IMNN-001 Plus Bevacizumab Accepted For Presentation At ASCO Annual Meeting

Imunon Abstract On Phase 2 Study With IMNN-001 Plus Bevacizumab Accepted For Presentation At ASCO Annual Meeting

BenzingaMay 15 20:44

Imunon Is Maintained at Buy by HC Wainwright & Co.

Imunon Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 14 19:09

HC Wainwright & Co. : Maintaining the Imunon (IMNN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $12.00.

HC Wainwright & Co. : Maintaining the Imunon (IMNN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $12.00.

Zhitong FinanceMay 14 19:02

HC Wainwright & Co. Maintains Buy on Imunon, Lowers Price Target to $12

HC Wainwright & Co. analyst Emily Bodnar maintains Imunon (NASDAQ:IMNN) with a Buy and lowers the price target from $13 to $12.

BenzingaMay 14 19:00

Imunon Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 775.91% HC Wainwright & Co. $13 → $12 Maintains Buy 04/01/2024 848.91% HC Wainwright & Co. $12

BenzingaMay 14 18:57

Imunon's Promising Clinical Trials and Strategic Advances Merit a Buy Rating

TipRanksMay 14 18:26

Q1 2024 Imunon Inc Earnings Call

Yahoo FinanceMay 14 18:08

Imunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...

Yahoo FinanceMay 14 15:02

Earnings Call Summary | Imunon(IMNN.US) Q1 2024 Earnings Conference

The following is a summary of the Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript:Financial Performance:Imunon reported a net loss for Q1 2024 of $4.9 million or $0.52 per share, a decrease from

Futu NewsMay 14 06:26 · Conference Call

Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript

Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 14 06:05

Imunon | 10-Q: Quarterly report

SEC announcementMay 13 20:14 · Announcements

Imunon GAAP EPS of -$0.52 Beats by $0.05

Seeking AlphaMay 13 20:06

Imunon 1Q Loss/Shr 52c >IMNN

Imunon 1Q Loss/Shr 52c >IMNN

Dow JonesMay 13 20:01

Imunon 1Q Research and Development Expenses $3.3M >IMNN

Imunon 1Q Research and Development Expenses $3.3M >IMNN

Dow JonesMay 13 20:01

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

PDF Version Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollmentTopline results expected this yearLAWRENCEVILLE, N.J., May 13,

ImunonMay 13 12:00

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

PDF Version Conference Call Begins Today at 11:00 a.m. Eastern TimeLAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company f

ImunonMay 13 12:00

IMUNON Appoints Stacy R. Lindborg As President And CEO, Effective May 13, 2024

Assumes leadership role as Company anticipates multiple near-term clinical milestonesBrings extensive leadership and experience in drug development and business strategyLAWRENCEVILLE, N.J., May 08, 20

BenzingaMay 8 20:14

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

PDF Version Assumes leadership role as Company anticipates multiple near-term clinical milestonesBrings extensive leadership and experience in drug development and business strategyLAWRENCEVILLE,

ImunonMay 8 12:00

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

PDF Version LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and nex

ImunonMay 6 12:00